Simcere Set For Hong Kong Relisting After New Venture Success

China’s Simcere Pharmaceutical Group is planning to return to the public market in Hong Kong this year, three years after delisting from the New York Stock Exchange. The company is building out an open platform and innovation incubator to support life science start-ups.

SHANGHAI - In one of the largest Hong Kong fundraisings for a health care firm from mainland China, Simcere Pharmaceutical Group is hoping to raise roughly $1bn in an initial public offering (IPO) in the third quarter of 2016.

Quoting sources familiar with the situation, The Wall Street Journal reported the financing plan, which it said would be led...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from China

More from Focus On Asia